Onconetix (ONCO) Return on Capital Employed (2022 - 2026)
Onconetix (ONCO) posted quarterly Return on Capital Employed of 92.26% for Q1 2026, up 52196.0% year-over-year from N/an in Q1 2025, and up 31.97% quarter-over-quarter from 135.62% in Q4 2025.
Onconetix (ONCO) Return on Capital Employed (2022 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Return on Capital Employed for 5 consecutive years, with 92.26% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 52196.0% year-over-year to 92.26%; the TTM figure through Mar 2026 stood at 92.26% (up 52196.0% YoY), while the FY2025 annual figure was 102.52%, up 4028.0% from the prior year.
- Return on Capital Employed improved to 92.26% in Q1 2026 per ONCO's latest filing, from 135.62% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 1731.74% in Q4 2024 and bottomed at 1476.82% in Q3 2025.
- Historically, Return on Capital Employed has averaged 18.65% across 5 years, with a median of 118.75% in 2023.
- Annual changes were most pronounced in 2024 — Return on Capital Employed soared 186101 bps — and 2025, when it plunged 186736 bps.
- Onconetix's Return on Capital Employed stood at 440.24% in 2022, then plunged by 129 bps to 129.27% in 2023, then soared by 1440 bps to 1731.74% in 2024, then plunged by 108 bps to 135.62% in 2025, then surged by 32 bps to 92.26% in 2026.
- Business Quant data shows ONCO's Return on Capital Employed at 92.26% in Q1 2026, 135.62% in Q4 2025, and 1476.82% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | -128.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -128.55% |
| Mar 31, 2026 | -92.26% |
| Dec 31, 2025 | -135.62% |
| Sep 30, 2025 | -1,476.82% |
| Jun 30, 2025 | -740.15% |
| Mar 31, 2025 | -614.21% |
| Dec 31, 2024 | 1,731.74% |
| Sep 30, 2024 | 382.33% |
| Jun 30, 2024 | -251.00% |
| Mar 31, 2024 | -73.98% |
| Dec 31, 2023 | -129.27% |
| Sep 30, 2023 | 1,176.10% |
| Jun 30, 2023 | -118.75% |
| Mar 31, 2023 | -160.71% |
| Dec 31, 2022 | 440.24% |
| Sep 30, 2022 | -146.36% |
| Jun 30, 2022 | -47.03% |
| Mar 31, 2022 | -61.39% |